Trial Application News Today

- OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study ...

Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer’s disease

ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of response

Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203

Press Release: Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights

ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and Phase

Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major Depressive Disorder Completion...

CTA1 approval by the ANSM2 and the EC3 of the phase 1 program resulting from the collaboration between Servier and Oncodesign Precision Medicine for the development of an innovative treatment in Parkinson's

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Toronto, ON (PRWEB) May 26, 2022 -- The European Union Clinical Trial Regulation (EU CTR) is the largest change in the EU clinical trial landscape in 20